Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Chimeric Antigen Receptor Modified T Cells Infusion Immunoproliferative Disorders	UNC Lineberger Comprehensive Cancer Center	P1/2	CCC (54)
Chimeric Antigen Receptor Modified T Cells Infusion Lymphatic Diseases	UNC Lineberger Comprehensive Cancer Center	P1/2	CCC (54)
ct103a Plasma Cell Myeloma	Chunrui Li	P1/2	CCC (54)
gt719 Hematopoietic And Lymphoid System Neoplasm	Grit Biotechnology	P1/2	CCC (54)
Jcar017 (Lisocabtagene Maraleucel) Indolent B-Cell Non-Hodgkin Lymphoma	Fred Hutchinson Cancer Center	P1/2	CCC (54)
TIL Effects of Immunotherapy	Shanghai Juncell Therapeutics	P1/2	CCC (54)
Platelets Liver Cirrhosis	Medical University of Vienna	P4	CCC (53)
Allogeneic Adipose-Derived Mesenchymal stromal cells (AD-MSCs) Diabetic Foot Ulcer	Medical University of Warsaw	P2	CCC (53)
Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes Cytomegalovirus Infection	M.D. Anderson Cancer Center	P2	CCC (53)
Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes Hematopoietic And Lymphoid Cell Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
allogeneic natural killer (NK) cells derived from umbilical cord blood, transduced with a Moloney murine leukaemia virus (MMLV)-based retroviral vector encoding inducible caspase-9 comprising human caspase-9 fused to a human FK506 binding protein variant (FKBP-F36V), a chimeric antigen receptor (CAR) targeting CD19 fused to CD28 and CD3 zeta signaling domains, and secretable human interleukin 15 (IL-15), linked together by T2A and E2A self-cleaving peptide sequences, respectively, under the control of the 5' long terminal repeat (LTR) MMLV promoter; the construct is flanked by 5' and 3' LTRs and contains an MMLV ? packaging signal and partial pol gene. The vector is pseudotyped with the envelope glycoprotein of gibbon ape leukaemia virus (GaLV). The cord blood mononuclear cells are treated with antibody-coated magnetic beads against CD19, CD3 and CD14 to remove B cells, T cells, and monocytes. The purified NK cells are then activated using an irradiated antigen presenting cell line (APC) in the presence of growth medium containing IL-2. Further depletion of residual CD3+ T cell may be performed using antibody-coated magnetic beads. The substance contains >80% NK cells (CD45+CD3-CD56+), of which with >21% are CAR positive, and secrete IL-15. B-Cell Non-Hodgkin Lymphoma	Takeda	P2	CCC (53)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. T-Cell Acute Lymphoblastic Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2	CCC (53)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	David Wald	P2	CCC (53)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Non-Small Cell Lung Carcinoma	BOE Technology Group Co., Ltd.	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells CBL-Related Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Central Nervous System Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Chromosomal Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Hereditary Persistence Of Fetal Hemoglobin	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Non-Hodgkin Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells B-Lymphoblastic Leukemia/Lymphoma With IAMP21	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Monosomy 7 Myelodysplasia And Leukemia Syndrome 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Myelodysplastic Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Neurofibromatosis Type 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)

Showing 226 to 250 of 3,774 assets

PreviousPage 10 of 151Next